{"id":20758,"date":"2023-07-09T12:42:17","date_gmt":"2023-07-09T12:42:17","guid":{"rendered":"https:\/\/health.theemtspot.com\/?p=20758"},"modified":"2026-04-16T09:23:11","modified_gmt":"2026-04-16T09:23:11","slug":"ace-inhibitors","status":"publish","type":"page","link":"https:\/\/www.theemtspot.com\/health\/blood-pressure\/medications\/ace-inhibitors\/","title":{"rendered":"ACE Inhibitors For High Blood Pressure: Types, Side Effects, Drug Interactions"},"content":{"rendered":"\n

ACE inhibitors are a class of prescription medications that block the angiotensin-converting enzyme, reducing blood pressure by preventing the formation of angiotensin II, a hormone that constricts blood vessels.<\/p>\n\n\n\n

Physicians prescribe ACE inhibitors for hypertension, heart failure, post-myocardial infarction recovery, and diabetic kidney disease.<\/p>\n\n\n\n

Clinical trials, including the CONSENSUS study and the SOLVD trial, demonstrated that ACE inhibitors reduce cardiovascular mortality in heart failure patients by 16\u201340% compared to placebo. (CONSENSUS Trial Study Group, N Engl J Med<\/em>, 1987; SOLVD Investigators, N Engl J Med<\/em>, 1991)<\/p>\n\n\n\n

Dry cough develops in 5\u201335% of patients taking ACE inhibitors, making it the most common reason for switching to an alternative drug class. (Irwin et al., Chest<\/em>, 2006)<\/p>\n\n\n\n

\n
\n
16-40%<\/div>\n
Reduction in cardiovascular mortality in heart failure patients vs. placebo (CONSENSUS, SOLVD trials)<\/div>\n <\/div>\n
\n
5-35%<\/div>\n
Of patients develop dry cough, the most common reason for switching to an ARB (Irwin et al., Chest, 2006)<\/div>\n <\/div>\n
\n
1-4 hrs<\/div>\n
Time to initial blood pressure lowering after first dose, depending on the specific agent<\/div>\n <\/div>\n
\n
2-4 weeks<\/div>\n
Time to maximum antihypertensive effect as the renin-angiotensin system reaches a new steady state<\/div>\n <\/div>\n<\/div>\n\n\n\n

The sections below cover how ACE inhibitors work, the six most commonly prescribed types, side effects, drug interactions, and dosing guidance.<\/p>\n\n\n\n

What Are Angiotensin-Converting Enzyme (ACE) Inhibitors?<\/span><\/h2>\n\n\n\n

ACE inhibitors, also known as angiotensin-converting enzyme inhibitors, are a type of medication utilized for the treatment of various ailments, primarily targeting hypertension (high blood pressure) and specific cardiac conditions.<\/strong><\/p>\n\n\n\n

They work by inhibiting the action of the enzyme called angiotensin-converting enzyme,<\/strong> which converts angiotensin I into a hormone called angiotensin II.<\/p>\n\n\n\n

ACE inhibitors function by inhibiting the actions of angiotensin II, a powerful vasoconstrictor that causes blood vessels to constrict and raises blood pressure.<\/p>\n\n\n\n

ACE inhibitors relax and dilate blood vessels, reduce fluid retention, and lower blood pressure by blocking angiotensin II from binding to vascular receptors.<\/p>\n\n\n\n

ACE inhibitors are also used for the following.<\/p>\n\n\n\n

\n
<\/div>
Heart failure:<\/strong> ACE inhibitors help improve symptoms, reduce hospitalizations, and prolong survival in patients with heart failure. (CONSENSUS Trial Study Group, N Engl J Med<\/em>, 1987; SOLVD Investigators, N Engl J Med<\/em>, 1991)<\/div><\/div>\n
<\/div>
Post-heart attack management:<\/strong> After experiencing a heart attack, healthcare professionals might prescribe these medications to enhance heart function and minimize the likelihood of subsequent cardiovascular incidents. (Pfeffer et al. (SAVE), N Engl J Med<\/em>, 1992)<\/div><\/div>\n
<\/div>
Diabetic kidney disease:<\/strong> ACE inhibitors can slow the progression of kidney damage in individuals with diabetes and high blood pressure. (Lewis et al., N Engl J Med<\/em>, 1993)<\/div><\/div>\n
<\/div>
Certain heart conditions:<\/strong> ACE inhibitors treat left ventricular dysfunction and reduce the risk of recurrent cardiovascular events in patients with established heart disease.<\/div><\/div>\n<\/div>\n\n\n\n

They may have potential side effects, and the choice of medication and dosage depends on individual factors and medical history.<\/strong><\/p>\n\n\n\n

What Are the Benefits of ACE Inhibitors Compared to Other Drugs?<\/span><\/h2>\n\n\n\n

ACE inhibitors lower blood pressure, reduce hospitalizations from heart failure, slow the progression of diabetic kidney disease, and combine safely with diuretics and calcium channel blockers.<\/p>\n\n\n\n

These advantages distinguish them from several other antihypertensive drug classes.<\/p>\n\n\n\n\n\n\n\n

\n
<\/div>
Effectiveness:<\/strong> ACE inhibitors are highly effective in lowering blood pressure. They work by blocking the action of angiotensin-converting enzyme, which helps relax and widen blood vessels, leading to a decrease in blood pressure. (Chobanian et al. (JNC 7), JAMA<\/em>, 2003)<\/div><\/div>\n
<\/div>
Heart protection:<\/strong> ACE inhibitors provide additional benefits beyond blood pressure reduction. They are known to protect the heart by improving symptoms and reducing hospitalizations in patients with heart failure. (CONSENSUS Trial Study Group, N Engl J Med<\/em>, 1987)<\/div><\/div>\n
<\/div>
Kidney protection:<\/strong> ACE inhibitors are beneficial for individuals with diabetic kidney disease or certain kidney conditions. They can slow the progression of kidney damage and help protect kidney function. (Lewis et al., N Engl J Med<\/em>, 1993)<\/div><\/div>\n
<\/div>
Potential for combination therapy:<\/strong> ACE inhibitors can be used in combination with other antihypertensive medications, such as diuretics or calcium channel blockers, to enhance their blood pressure-lowering effects.<\/div><\/div>\n
<\/div>
Well-tolerated:<\/strong> ACE inhibitors are well-tolerated by most patients. Common side effects, such as a dry cough or dizziness, are usually mild and reversible.<\/div><\/div>\n<\/div>\n\n\n\n

Medication alone does not replace the role of nutrition in blood pressure management; physicians typically combine ACE inhibitor therapy with dietary approaches to blood pressure control<\/a> for greater long-term effect.<\/p>\n\n\n\n

What Are the Types of ACE Inhibitors?<\/span><\/h2>\n\n\n\n

Six ACE inhibitors are most commonly prescribed: lisinopril, enalapril, ramipril, captopril, quinapril, and perindopril.<\/p>\n\n\n\n

Each shares the same core mechanism of blocking angiotensin II formation while differing in half-life, approved indications, and tolerability profile.<\/p>\n\n\n\n

Common examples of ACE inhibitors include following.<\/p>\n\n\n\n

\n
\n

Lisinopril<\/p>\n

One of the most commonly prescribed ACE inhibitors. Used to treat hypertension, heart failure, and improve survival rates following a heart attack.<\/p>\n <\/div>\n

\n

Enalapril<\/p>\n

Used to treat high blood pressure, heart failure, and certain kidney conditions.<\/p>\n <\/div>\n

\n

Ramipril<\/p>\n

Reduces blood pressure, lowers the risk of heart failure hospitalizations, and decreases the incidence of heart attacks, strokes, and cardiovascular death in high-risk patients.<\/p>\n <\/div>\n

\n

Captopril<\/p>\n

Used to manage hypertension, heart failure, and to improve survival rates after a heart attack. May also be prescribed for certain kidney conditions.<\/p>\n <\/div>\n

\n

Quinapril<\/p>\n

Used to treat hypertension and heart failure. May also be prescribed to help protect the kidneys in individuals with diabetes.<\/p>\n <\/div>\n

\n

Perindopril<\/p>\n

Reduces blood pressure, stabilizes heart failure, and lowers the risk of cardiovascular events in patients with a prior history of heart disease.<\/p>\n <\/div>\n<\/div>\n\n\n\n

The table below compares the six most commonly prescribed ACE inhibitors by typical adult dose, primary approved indications, and approximate half-life.<\/p>\n\n\n\n

\n \n \n \n \n \n \n \n \n \n \n
Drug<\/th>\n Typical Adult Dose<\/th>\n Primary Indications<\/th>\n Half-Life (h)<\/th>\n <\/tr>\n <\/thead>\n
Lisinopril<\/strong><\/td>\n 10-40 mg once daily<\/td>\n Hypertension, heart failure, post-MI<\/td>\n 12<\/td>\n <\/tr>\n
Enalapril<\/strong><\/td>\n 5-20 mg twice daily<\/td>\n Hypertension, heart failure, diabetic nephropathy<\/td>\n 11<\/td>\n <\/tr>\n
Ramipril<\/strong><\/td>\n 2.5-10 mg once daily<\/td>\n Hypertension, heart failure, CV risk reduction (HOPE)<\/td>\n 13-17<\/td>\n <\/tr>\n
Captopril<\/strong><\/td>\n 25-50 mg two to three times daily<\/td>\n Hypertension, heart failure, post-MI, diabetic nephropathy<\/td>\n 2<\/td>\n <\/tr>\n
Quinapril<\/strong><\/td>\n 10-80 mg once daily<\/td>\n Hypertension, heart failure<\/td>\n 2 (active metabolite ~25)<\/td>\n <\/tr>\n
Perindopril<\/strong><\/td>\n 4-8 mg once daily<\/td>\n Hypertension, stable CAD, heart failure<\/td>\n 10-12<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n\n\n

The choice of ACE inhibitor may depend<\/strong> on various factors, such as the individual’s medical condition, response to treatment<\/strong>, and potential side effects<\/strong>.<\/p>\n\n\n\n

What Are the Possible Side Effects of ACE Inhibitors?<\/span><\/h2>\n\n\n\n

The table below lists the known side effects of ACE inhibitors, their approximate reported frequency, and the standard clinical management for each.<\/p>\n\n\n\n

\n
\n
\n
Dry cough<\/div>\n
5-35% of patients<\/div>\n <\/div>\n
Switch to ARB (angiotensin receptor blocker) if intolerable. Cough results from bradykinin accumulation in the respiratory tract and resolves within 1-4 weeks of discontinuing the medication.<\/div>\n <\/div>\n
\n
\n
Dizziness or lightheadedness<\/div>\n
Common (varies by dose)<\/div>\n <\/div>\n
Dose reduction; take at bedtime; monitor blood pressure. Most pronounced after the first dose or following a dose increase.<\/div>\n <\/div>\n
\n
\n
Angioedema<\/div>\n
0.1-0.7% of patients<\/div>\n <\/div>\n
Discontinue immediately; seek emergency care if airway involved. Patients with a history of ACE inhibitor-induced angioedema must never restart any ACE inhibitor.<\/div>\n <\/div>\n
\n
\n
Hyperkalemia<\/div>\n
Higher risk with renal impairment<\/div>\n <\/div>\n
Dietary potassium restriction; serum potassium monitoring. Risk increases significantly when combined with potassium-sparing diuretics.<\/div>\n <\/div>\n
\n
\n
Kidney function decline<\/div>\n
Risk higher in bilateral renal artery stenosis<\/div>\n <\/div>\n
Monitor creatinine and eGFR; discontinue if significant rise. A small initial rise in creatinine (up to 30%) is acceptable; a larger rise warrants reassessment.<\/div>\n <\/div>\n
\n
\n
Fatigue or weakness<\/div>\n
Uncommon<\/div>\n <\/div>\n
Reassess dose; rule out hypotension as the underlying cause.<\/div>\n <\/div>\n
\n
\n
Nausea or rash<\/div>\n
Uncommon<\/div>\n <\/div>\n
Symptomatic treatment; consider switching to a different ACE inhibitor within the same class.<\/div>\n <\/div>\n<\/div>\n\n\n\n

The severity and occurrence of side effects can vary from person to person.<\/p>\n\n\n\n

Tracking blood pressure readings during treatment<\/a> helps a physician detect early adverse responses and adjust the dosage accordingly.<\/p>\n\n\n\n

Consult your doctor immediately if you experience any of the above-mentioned problems.<\/p>\n\n\n\n

What Drugs Interfere With ACE Inhibitors?<\/span><\/h2>\n\n\n\n

The table below summarizes the most clinically significant drug interactions with ACE inhibitors, the mechanism driving each interaction, and the associated risk.<\/p>\n\n\n\n

\n \n \n \n \n \n \n \n \n \n
Interacting Drug<\/th>\n Mechanism<\/th>\n Risk<\/th>\n <\/tr>\n <\/thead>\n
NSAIDs (ibuprofen, naproxen)<\/strong><\/td>\n Inhibit prostaglandin-mediated vasodilation, reducing ACE inhibitor antihypertensive effect and impairing renal perfusion<\/td>\n Reduced BP control; acute kidney injury in susceptible patients<\/td>\n <\/tr>\n
Potassium-sparing diuretics (spironolactone)<\/strong><\/td>\n Both agents independently raise serum potassium; combined use is additive<\/td>\n Hyperkalemia; cardiac arrhythmia risk<\/td>\n <\/tr>\n
Lithium<\/strong><\/td>\n ACE inhibitors reduce lithium renal clearance, raising plasma lithium concentration<\/td>\n Lithium toxicity; requires close serum monitoring<\/td>\n <\/tr>\n
Loop and thiazide diuretics<\/strong><\/td>\n Volume depletion amplifies ACE inhibitor-induced hypotension<\/td>\n Symptomatic hypotension, especially on first dose<\/td>\n <\/tr>\n
Beta-blockers \/ calcium channel blockers<\/strong><\/td>\n Additive antihypertensive effect through complementary mechanisms<\/td>\n Enhanced BP lowering (beneficial in combination therapy); excess hypotension if doses not titrated<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n\n\n

Inform your doctor about all medications, supplements, and herbal products to avoid any possible interactions.<\/p>\n\n\n\n

Cited evidence for specific interactions: spironolactone-ACE inhibitor hyperkalemia risk (Juurlink et al., JAMA<\/em>, 2004); lithium toxicity with ACE inhibitors (Finley et al., Clin Pharmacokinet<\/em>, 1996); NSAIDs reducing ACE inhibitor efficacy (\u017ar\u00f3d\u0142o: weryfikacja wymagana).<\/p>\n\n\n\n

Drug interactions that affect vascular tone can also widen the gap between systolic and diastolic values.<\/p>\n\n\n\n

Physicians use pulse pressure as a cardiovascular risk marker<\/a> to identify patients requiring closer monitoring during combination therapy.<\/p>\n\n\n\n

How To Use ACE Inhibitors?<\/span><\/h2>\n\n\n\n

ACE inhibitors are taken orally once or twice daily, at the dose and schedule prescribed by your physician.<\/p>\n\n\n\n

Self-adjustment of dose or abrupt discontinuation carries the risk of rebound hypertension.<\/p>\n\n\n\n

\n
\n
1<\/div>\n
Take at the same time each day.<\/strong> Consistent timing maintains stable plasma levels and supports optimal blood pressure control.<\/div>\n <\/div>\n
\n
2<\/div>\n
Take with or without food.<\/strong> ACE inhibitors are absorbed adequately regardless of meals; captopril absorption is modestly reduced by food, so it is best taken 1 hour before eating.<\/div>\n <\/div>\n
\n
3<\/div>\n
Handle a missed dose correctly.<\/strong> Take the missed dose as soon as you remember, unless the next scheduled dose is within 4 hours. In that case, skip the missed dose entirely.<\/div>\n <\/div>\n
\n
4<\/div>\n
Do not stop without consulting your doctor.<\/strong> Abrupt discontinuation can cause a rapid rise in blood pressure.<\/div>\n <\/div>\n
\n
5<\/div>\n
Attend regular follow-up appointments.<\/strong> Monitoring of blood pressure, kidney function (creatinine, eGFR), and serum potassium is required, typically at 1-4 weeks after initiation or dose change, then every 3-6 months.<\/div>\n <\/div>\n<\/div>\n\n\n\n

Using a validated cuff device for blood pressure monitoring at home<\/a> provides the physician with additional readings between clinic visits, improving the accuracy of dosage decisions.<\/p>\n\n\n\n

Who Should Not Take ACE Inhibitors?<\/span><\/h2>\n\n\n\n

ACE inhibitors are contraindicated in pregnancy from the second trimester onward, as they cause fetal renal dysgenesis, oligohydramnios, and neonatal renal failure. The FDA classifies them as Category D teratogens in the second and third trimesters.<\/p>\n\n\n\n

Patients with a confirmed history of ACE inhibitor-induced angioedema must not restart any ACE inhibitor, as re-exposure carries a risk of recurrent, potentially life-threatening airway swelling.<\/p>\n\n\n\n

Bilateral renal artery stenosis is a contraindication because ACE inhibitors reduce efferent arteriolar tone in the kidney, causing a critical drop in glomerular filtration pressure when both renal arteries are narrowed.<\/p>\n\n\n\n

Severe hyperkalemia above 5.5 mmol\/L is a contraindication, as ACE inhibitors reduce aldosterone secretion and further raise serum potassium, increasing the risk of cardiac arrhythmia.<\/p>\n\n\n\n

The table below summarizes absolute and relative contraindications with the clinical rationale for each.<\/p>\n\n\n\n

\n \n \n \n \n \n \n \n \n \n \n
Contraindication<\/th>\n Type<\/th>\n Clinical Rationale<\/th>\n <\/tr>\n <\/thead>\n
Pregnancy (2nd and 3rd trimester)<\/strong><\/td>\n Absolute<\/span><\/td>\n Fetal renal dysgenesis, oligohydramnios, neonatal renal failure<\/td>\n <\/tr>\n
History of ACE inhibitor-induced angioedema<\/strong><\/td>\n Absolute<\/span><\/td>\n Risk of recurrent airway-threatening angioedema on re-exposure<\/td>\n <\/tr>\n
Bilateral renal artery stenosis<\/strong><\/td>\n Absolute<\/span><\/td>\n Loss of efferent arteriolar tone causes acute kidney injury<\/td>\n <\/tr>\n
Severe hyperkalemia (K+ above 5.5 mmol\/L)<\/strong><\/td>\n Absolute<\/span><\/td>\n Additive potassium retention increases arrhythmia risk<\/td>\n <\/tr>\n
Significant aortic or mitral stenosis<\/strong><\/td>\n Relative<\/span><\/td>\n Vasodilation may critically reduce cardiac output<\/td>\n <\/tr>\n
eGFR below 30 mL\/min\/1.73 m\u00b2<\/strong><\/td>\n Relative<\/span><\/td>\n Increased risk of hyperkalemia and acute kidney injury; requires dose adjustment and close monitoring<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n\n\n

ACE Inhibitors vs. ARBs: What Is the Difference?<\/span><\/h2>\n\n\n\n

ACE inhibitors and ARBs (angiotensin receptor blockers) both lower blood pressure by targeting the renin-angiotensin-aldosterone system, but at different points in the cascade.<\/p>\n\n\n\n

ACE inhibitors block the enzyme that converts angiotensin I into angiotensin II, while ARBs block the AT1 receptor that angiotensin II binds to. This distinction explains the key difference in their side effect profiles.<\/p>\n\n\n\n

ACE inhibitors also prevent the breakdown of bradykinin, a peptide that accumulates in the respiratory tract and triggers dry cough in 5\u201335% of patients; ARBs do not inhibit bradykinin degradation, so they produce cough at a rate similar to placebo.<\/p>\n\n\n\n

Current clinical guidelines recommend switching to an ARB when ACE inhibitor-induced cough is intolerable, as the two drug classes produce equivalent blood pressure reduction and cardiovascular protection in most patient populations.<\/p>\n\n\n\n

The table below compares ACE inhibitors and ARBs across the dimensions most relevant to clinical decision-making.<\/p>\n\n\n\n

\n \n \n \n \n \n \n \n \n \n \n \n
Feature<\/th>\n ACE Inhibitors<\/th>\n ARBs<\/th>\n <\/tr>\n <\/thead>\n
Mechanism<\/strong><\/td>\n Block ACE enzyme, preventing angiotensin II production<\/td>\n Block AT1 receptor, preventing angiotensin II from acting<\/td>\n <\/tr>\n
Dry cough incidence<\/strong><\/td>\n 5-35% of patients<\/td>\n Similar to placebo (1-3%)<\/td>\n <\/tr>\n
Angioedema risk<\/strong><\/td>\n 0.1-0.7%<\/td>\n Lower, but not zero<\/td>\n <\/tr>\n
Bradykinin effect<\/strong><\/td>\n Increases bradykinin (vasodilatory benefit; causes cough)<\/td>\n No effect on bradykinin<\/td>\n <\/tr>\n
Evidence in heart failure<\/strong><\/td>\n Extensive RCT evidence (CONSENSUS, SOLVD, ATLAS)<\/td>\n Comparable (CHARM, Val-HeFT)<\/td>\n <\/tr>\n
Use in pregnancy<\/strong><\/td>\n Contraindicated (Category D, 2nd-3rd trimester)<\/td>\n Contraindicated (same fetal risk)<\/td>\n <\/tr>\n
Cost<\/strong><\/td>\n Generally lower (most are generic)<\/td>\n Slightly higher on average<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/div>\n\n\n\n

Frequently Asked Questions About ACE Inhibitors<\/span><\/h2>\n\n\n\n
\n
\n

What Do ACE Inhibitors Do to Blood Pressure?<\/h3>\n
\n

ACE inhibitors block the angiotensin-converting enzyme from producing angiotensin II, a hormone that constricts blood vessels.<\/p>\n

By preventing angiotensin II formation, ACE inhibitors relax and widen blood vessels, reducing peripheral vascular resistance and lowering systolic and diastolic blood pressure.<\/p>\n <\/div>\n <\/div>\n

\n

How Long Does It Take for ACE Inhibitors to Lower Blood Pressure?<\/h3>\n
\n

ACE inhibitors begin lowering blood pressure within 1-4 hours of the first dose, depending on the specific agent.<\/p>\n

Maximum antihypertensive effect typically occurs within 2-4 weeks of initiating therapy as the renin-angiotensin system reaches a new steady state.<\/p>\n <\/div>\n <\/div>\n

\n

What Is the Most Common Side Effect of ACE Inhibitors?<\/h3>\n
\n

Dry, persistent cough is the most common side effect of ACE inhibitors, affecting 5-35% of patients.<\/p>\n

The cough results from bradykinin accumulation in the respiratory tract, a direct consequence of ACE inhibition, and resolves within 1-4 weeks of discontinuing the medication.<\/p>\n <\/div>\n <\/div>\n

\n

Can You Take ACE Inhibitors With Ibuprofen?<\/h3>\n
\n

Combining ACE inhibitors with ibuprofen or other NSAIDs reduces the antihypertensive effectiveness of ACE inhibitors and increases the risk of acute kidney injury.<\/p>\n

Physicians recommend paracetamol (acetaminophen) as the preferred analgesic for patients on ACE inhibitor therapy when pain relief is required.<\/p>\n <\/div>\n <\/div>\n

\n

Who Should Not Take ACE Inhibitors?<\/h3>\n
\n

ACE inhibitors are contraindicated in pregnancy, as they cause fetal renal dysgenesis and are classified as Category D teratogens from the second trimester onward.<\/p>\n

Additional contraindications include a prior history of ACE inhibitor-induced angioedema, bilateral renal artery stenosis, and severe hyperkalemia above 5.5 mmol\/L.<\/p>\n <\/div>\n <\/div>\n

\n

What Is the Difference Between ACE Inhibitors and ARBs?<\/h3>\n
\n

ACE inhibitors block the enzyme that produces angiotensin II, while ARBs (angiotensin receptor blockers) block the receptor that angiotensin II binds to. Both drug classes lower blood pressure through the renin-angiotensin system but at different points in the cascade.<\/p>\n

ARBs do not cause bradykinin accumulation and therefore produce significantly less cough, making them the standard alternative for patients who cannot tolerate ACE inhibitor-induced cough.<\/p>\n <\/div>\n <\/div>\n

\n

Can ACE Inhibitors Be Taken Long-Term?<\/h3>\n
\n

ACE inhibitors are prescribed as long-term or lifelong therapy in hypertension, heart failure, and diabetic kidney disease, with clinical trial evidence spanning up to 5 years of continuous use.<\/p>\n

Long-term use requires periodic monitoring of serum potassium and kidney function to detect hyperkalemia or progressive renal impairment.<\/p>\n <\/div>\n <\/div>\n<\/div>\n\n\n\n